P
USRE45992EActiveUtilityPatentIndex 89

Optimized FC variants

Assignee: LAB FRANCAIS DU FRACTIONNEMENTPriority: Mar 20, 2009Filed: Mar 19, 2010Granted: May 3, 2016
Est. expiryMar 20, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:BEHRENS CHRISTIANJORIEUX SYLVIEKHARRAT ABDELHAKIMBOUAYADI KHALILMONDON PHILIPPEMONNET-MARS CELINE
A61P 37/00A61P 37/08A61P 7/00A61P 37/06A61P 25/00A61P 35/00A61P 29/00A61P 35/02A61P 31/00A61P 11/06A61P 1/00A61P 11/00A61P 19/02A61P 19/04A61P 1/04C07K 2317/92C07K 2317/21C07K 16/00C07K 2317/52A61K 39/395C07K 16/28
89
PatentIndex Score
15
Cited by
14
References
10
Claims

Abstract

A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A variant of a parent polypeptide comprising a Fc region, which variant exhibits increased binding to FcRn as compared to said parent polypeptide and comprises
 a combination of amino acid modifications selected from the group consisting of: 
 N315D/A330V/N361D/A378V/N434Y, 
 V264E/N315D/A378V/N390S/G420R/N434Y, 
 N315D/A378V/N434Y, 
 N315D/A330V/A378V/N434Y, 
 N315D/K334E/A378V/N434Y, 
 V264E/N315D/A378V, 
 P228R/N315D/A330V/N361D/A378V/N434Y, 
 P228R/P230S/N315D/A330V/N361D/A378V/N434Y, 
 P228L/N315D/A330V/N361D/A378V/N434Y, 
 P228L/P230S/N315D/A330V/N361D/A378V/N434Y, 
 P230S/N315D/A330V/N361D/A378V/N434Y, 
 P230T/V264E/N315D/K370R/A378V, 
 of the Fc region, wherein the numbering of the amino acids in the Fc region is that of the EU index as in Kabat. 
 
     
     
       2. The variant according to  claim 1 , wherein said variant is an antibody. 
     
     
       3. The variant according to  claim 2 , wherein said antibody is an IgG antibody. 
     
     
       4. A pharmaceutical composition comprising a variant as defined in  claim 1 . 
     
     
       5. A medicament comprising a variant according to  claim 1 . 
     
     
       6. An isolated nucleic acid encoding a variant as defined in  claim 1 . 
     
     
       7. A vector comprising the nucleic acid of  claim 6 . 
     
     
       8. An isolated host cell containing the vector of  claim 7 . 
     
     
       9. A method for producing a variant according to  claim 1 , comprising culturing a host cell containing a vector comprising an isolated nucleic acid encoding said variant so that the nucleic acid is expressed. 
     
     
       10. A variant according to claim 1, wherein the Fc region of the parent polypeptide is SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.